Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry.
Nanna MG, Navar AM, Wang TY, Li S, Virani SS, Li Z, Robinson JG, Roger VL, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED. Nanna MG, et al. Among authors: koren a. Am Heart J. 2019 Aug;214:113-124. doi: 10.1016/j.ahj.2019.05.009. Epub 2019 May 22. Am Heart J. 2019. PMID: 31202098 Free PMC article.
Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.
Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, Koren A, Neumann P, Menzin J. Lin I, et al. Among authors: koren a. J Manag Care Spec Pharm. 2016 Jun;22(6):685-98. doi: 10.18553/jmcp.2016.22.6.685. J Manag Care Spec Pharm. 2016. PMID: 27231796 Free PMC article.
Only 15.0% of the population initiated therapy with a high-intensity statin, and 22.5% of these high-intensity statin initiators switched to a moderate- to low-intensity regimen during the follow-up period. ...Duration of treatment was longer among those who were tr …
Only 15.0% of the population initiated therapy with a high-intensity statin, and 22.5% of these high-intensity statin initiators swit …
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. McCullough PA, et al. Among authors: koren a. Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040. Epub 2018 Feb 2. Am J Cardiol. 2018. PMID: 29472008 Free article.
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M. Toth PP, et al. Among authors: koren a. Kidney Int. 2018 Jun;93(6):1397-1408. doi: 10.1016/j.kint.2017.12.011. Epub 2018 Mar 8. Kidney Int. 2018. PMID: 29526502 Free article.
Sex Differences in the Use of Statins in Community Practice.
Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Li Z, Peterson ED, Navar AM. Nanna MG, et al. Among authors: koren a. Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005562. doi: 10.1161/CIRCOUTCOMES.118.005562. Epub 2019 Aug 16. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31416347 Free PMC article.
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.
Xian Y, Navar AM, Li S, Li Z, Robinson J, Virani SS, Louie MJ, Koren A, Goldberg A, Roger VL, Wilson PWF, Peterson ED, Wang TY. Xian Y, et al. Among authors: koren a. J Am Heart Assoc. 2019 Oct;8(19):e013229. doi: 10.1161/JAHA.119.013229. Epub 2019 Sep 26. J Am Heart Assoc. 2019. PMID: 31554462 Free PMC article.
Statin Therapy and Risk of Incident Diabetes Mellitus in Adults With Cardiovascular Risk Factors.
Go AS, Ambrosy AP, Kheder K, Fan D, Sung SH, Inveiss AI, Romo-LeTourneau V, Thomas SM, Koren A, Lo JC; Kaiser Permanente Cholesterol-Lowering Therapy in High-Risk Adults: Management and Patient Risks (KP CHAMP) Study. Go AS, et al. Among authors: koren a. Am J Cardiol. 2020 Feb 15;125(4):534-541. doi: 10.1016/j.amjcard.2019.11.011. Epub 2019 Nov 19. Am J Cardiol. 2020. PMID: 31848029
392 results